Navigation Links
Watson Confirms Favorable Appeals Court Ruling on Generic SEASONIQUE® Patent Challenge
Date:3/25/2011

MORRISTOWN, N.J., March 25, 2011 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading integrated global pharmaceutical company, today confirmed that it has received a favorable decision from the U.S. Court of Appeals for the Federal Circuit related to its ongoing patent challenge in connection with Watson's Abbreviated New Drug Application (ANDA) seeking FDA approval to market a generic version of Teva Women's Health, Inc.'s SEASONIQUE® (levonorgestrel/ethinyl estradiol (0.15 mg/0.03 mg) and ethinyl estradiol (0.01 mg)).

The Appeals Court reversed and remanded for trial a March 31, 2010 summary judgment order from the United States District Court for the District of Nevada regarding United States Patent No. 7,320,969 (the '969 patent).  On January 22, 2008, Watson notified Teva Women's Health that Watson's ANDA contained a paragraph IV certification asserting that the '969 patent is invalid, unenforceable and/or not infringed.  Based on available information, Watson believes it may be the "first applicant" for a generic version of SEASONIQUE® and, should its product be approved, it may be entitled to 180 days of generic market exclusivity.

SEASONIQUE® is indicated for the prevention of pregnancy.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc. is a leading integrated global pharmaceutical company.  The Company is engaged in the development and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health.  Watson has operations in many of the world's established and growing international markets.

For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

Forward-Looking Statement

Statements co
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Watson Launches Generic Biaxin(R) XL
2. Watson Announces Positive Results From Its Pivotal Study of Oxybutynin Topical Gel for the Treatment of Overactive Bladder
3. Watson Announces Silodosin NDA Accepted for Filing by FDA for the Treatment of Benign Prostatic Hyperplasia
4. Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder
5. Watson Announces United States Availability of RAPAFLO(TM) (silodosin), a Novel New Treatment in Benign Prostatic Hyperplasia (BPH)
6. Watson and Barr Settle Lawsuit Over Oxytrol(R)
7. Watson to Host Conference Call and Webcast to Discuss Fourth Quarter 2009 Earnings and 2010 Outlook
8. Watson Completes Acquisition of Eden Biodesign
9. Watson to Present at Credit Suisse Healthcare Conference
10. Watson Announces New Program to Help Promote Good Bone Health in Advanced Prostate Cancer Patients on Long-Term Androgen Deprivation Therapy
11. Watson Files FDA Application for Generic Rozerem(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... 18, 2013  Intercept Pharmaceuticals, Inc.  (NASDAQ: ... the development and commercialization of novel bile acid therapeutics ... of an underwritten public offering of 1,730,000 shares of ... $33.01 per share.  In addition, Intercept has granted the ... additional 259,500 shares of common stock. All ...
(Date:6/18/2013)... PROSPECT, Ill. , June 18, 2013 /PRNewswire-iReach/ ... of its new X3130 Appliance Inlet Module. The ... circuit breaker , combines a C14 appliance inlet ... one compact package.  This three-in-one device allows design ... their designs - cutting installation time by 66 ...
(Date:6/18/2013)... June 18, 2013  It has become apparent ... Seating and Mobility, a subsidiary company of The ... repair. This appears to be due to the ... field service employees.  (Logo: ... of these clients are complex mobility users with ...
Breaking Medicine Technology:Intercept Pharmaceuticals Announces Pricing of Public Offering of Common Stock 2Three-in-One X3130 Appliance Inlet Module 2
... Nov. 29, 2011 Uptake Medical® today announced the ... lung volume reduction in a patient with severe emphysema. ... endoscopic lung volume reduction system for the treatment of ... without leaving foreign materials in the lung. The patient ...
... IRVING, Texas, Nov. 29, 2011 A new study in ... has uncovered a novel mechanism that cancer cells may use ... "Tumor-infiltrating myeloid cells induce tumor cell resistance to cytotoxic T ... Moffitt Cancer Center in Tampa, Fla., shows that a specific ...
Cached Medicine Technology:Uptake Medical Announces First Commercial Use of InterVapor for Patients With Severe Emphysema 2Uptake Medical Announces First Commercial Use of InterVapor for Patients With Severe Emphysema 3New Study Points to Novel Mechanism by Which Tumors Escape Recognition by the Immune System 2New Study Points to Novel Mechanism by Which Tumors Escape Recognition by the Immune System 3
(Date:6/19/2013)... According to Transparency Market Research “Endoscopy devices ... and Forecast, 2011 – 2017,” the global endoscopy devices ... 2011 and is expected to reach USD 10.8 billion ... 2011 to 2017. Flexible endoscopes formed the largest category ... million for the year 2011. , Related Report : ...
(Date:6/19/2013)... is many fold higher in persons over 65 years ... how best to treat these older cancer patients. Furthermore, ... trials, those elderly patients who are eventually included are ... patient population is not well represented in clinical trials. ... now starting a new phase 2 trial in precisely ...
(Date:6/19/2013)... 2013 Ethigen announced today the US ... service , providing next-generation sequencing (NGS) and rearrangement analysis ... part of an expanded hereditary cancer panel, including full ... links to cancer risk: MLH1, MSH2, MSH6, APC, MUTYH ... FH, FLCN, PDGFRA, and KIT. , The expanded ...
(Date:6/19/2013)... Angeles, California (PRWEB) June 19, 2013 ... for iPhone, a free music and fitness app for ... you can discover new Spotify songs that match your ... when they exercise, and add songs to your favorite ... and songs curated by the GoTunes staff. , Get ...
(Date:6/19/2013)... (PRWEB) June 19, 2013 The reason for ... is because users can place a 4x8 flood tray inside ... space to work around. In addition, Gorilla Grow Tents ... they are the tallest, thickest and strongest grow tents on ... for grow tent standards. , Gorilla Grow Tents ...
Breaking Medicine News(10 mins):Health News:Endoscopy Devices Market Will Reach USD 10.8 Billion in 2017 : Transparency Market Research 2Health News:Endoscopy Devices Market Will Reach USD 10.8 Billion in 2017 : Transparency Market Research 3Health News:EORTC study opens for elderly patients with HER-2 positive metastatic breast cancer 2Health News:Ethigen Launches Next Generation (NGS) BRCA Testing With Expanded Hereditary Cancer Panel 2Health News:Ethigen Launches Next Generation (NGS) BRCA Testing With Expanded Hereditary Cancer Panel 3Health News:The GoTunes Iphone App Creates a Streaming Workout Music Community Via Spotify 2Health News:Stealth Grow Tent Brand’s Popularity Rises 2
... , , , , , ... -- Mindray Medical,International Limited (NYSE: MR ), a ... shareholder resolutions,adopted at its annual general meeting of shareholders held ... At the meeting, Mindray Medical International,s shareholders approved the,re-election ...
... finds , FRIDAY, Dec. 18 (HealthDay News) -- Long-term ... may not be able to regain full stability while ... gait and balance become stable. However, even with prolonged ... difficulty in standing upright. Their balance can be marked ...
... Dec. 18 Memorial Blood Centers is pleased to have ... 22, 2009 at the City of Duluth Employees Blood Drive. Following ... be an open house at Memorial Blood Centers in Duluth from ... aging and unreliable bloodmobile and will allow Memorial Blood Centers to ...
... , WASHINGTON, Dec. 18 Since ... largely by the U.S. Agency for International Development (USAID), ... critical insight for decision makers to plan, monitor, and ... staff has helped conduct some 260 surveys in over ...
... blacks, study finds , FRIDAY, Dec. 18 (HealthDay News) -- ... are more likely to skip taking their meds, a new ... patients, aged 60 and older, who were interviewed at the ... year later. , Overall, whites used more medications, had more ...
... CentraCare president is new chair , ST. PAUL, Minn., ... health systems, recently elected or re-elected the following members to its board ... Chair - Terence Pladson, M.D., president, CentraCare Health System, ... Klimp, CEO, Queen of Peace Hospital, New Prague, Secretary/treasurer ...
Cached Medicine News:Health News:Mindray Medical International Limited Announces Shareholder Resolutions Adopted at 2009 Annual General Meeting 2Health News:Alcoholics May Never Fully Regain Balance 2Health News:Memorial Blood Centers Showcases New Vehicle 2Health News:USAID Celebrates 25 Years of Demographic and Health Surveys 2Health News:Medication Adherence Varies Between Races 2Health News:Minnesota Hospital Association Elects, Re-Elects Members to Board 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: